[1] Senan S, Lagerwaard FJ. The role of radiotherapy in non-small-cell lung cancer[J]. Ann Oncol, 2005, 16 suppl 2:S223-228. DOI:10.1093/annonc/mdi726.
[2] Ozgen A, Hayran M, Kahraman F. Mean esophageal radiation dose is predictive of the grade of acute esophagitis in lung cancer patients treated with concurrent radiotherapy and chemotherapy[J].J Radiat Res, 2012, 53(6):916-922. DOI:10.1093/jrr/rrs056.
[3] Walker DM, Kajon AE, Torres SM, et al. WR1065 mitigates AZT-ddI-Induced mutagenesis and inhibits viral replication[J]. Environ Mol Mutagen, 2009, 50(6):460-472. DOI:10.1002/em.20482.
[4] 刘彩彩.局部晚期非小细胞肺癌放疗中阿米福汀的作用研究[J].母婴世界, 2015, 15:16.
Liu CC. Study on the effect of amifostine in local advanced NSCLC radiotherapy[J]. Mother Child World, 2015, 15:16.
[5] 赵衍.阿米福汀在非小细胞肺癌放疗中对正常组织的保护研究[J].临床肺科杂志, 2014, 19(11):2050-2052. DOI:10.3969/j.issn.1009-6663. 2014.011.036.
Zhao Y. Amifostine protective effect for normal tissue in the radiotherapy of non-small cell lung cancer[J]. J Clinic Pulmonary Med, 2014, 19(11):2050-2052.  doi: 10.3969/j.issn.1009-6663.2014.011.036
[6] Movsas B, Scot C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancerpatients receiving chemotherapy and hyperfractionated radiation:radiationtherapy oncology group trial 98-01[J]. J Clin Oncol, 2005, 23(10):2145-2154. DOI:10.1200/JCO. 2005.07.167.
[7] Senzer N. A phase Ⅲ randomized evaluation of amifostine in stage ⅢA/ⅢB non-small celllung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification:preliminary findings[J].Semin Oncol, 2002, 29(6 suppl 19):S38-41. DOI:10.1053/sonc.2002.37361.
[8] Koukourakis MI. Amifostine:is there evidence of tumor protection?[J]. Semin Oncol, 2003, 30(6 Suppl 18):S18-30. DOI:10.1053/j.seminoncol.2003.11.014.
[9] Shuster JJ. Review:Cochrane handbook forsystematic reviews for interventions, Version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors[J]. Res Syn Meth, 2011, 2(2):126-130. DOI:10.1002/jrsm.38.
[10] DerSimonian R, Laird N. Meta-analysis in clinical trials[J]. Control Clin Trials, 1986, 7(3):177-188.  doi: 10.1016/0197-2456(86)90046-2
[11] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses[J]. BMJ, 2003, 327(7414):557-560. DOI:10.1136/bmj.327.7414.557.
[12] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test[J]. BMJ, 1997, 315(7109):629-634. DOI:10.1136/bmj.315.7109.629.
[13] 林展, 严浩林, 朱海生, 等.阿米福汀在局部晚期非小细胞肺癌放疗中的作用研究[J].中国全科医学, 2013, 16(4):1247-1249. DOI:10.3969/j.issn.1007-9572. 2013.04.053.
Lin Z, Yan HL, Zhu HS, et al. Short-term effects of amifostine on locally advanced NSCLC patients treated with radiotherapy[J]. Chin Gen Pract, 2013, 16(4):1247-1249.  doi: 10.3969/j.issn.1007-9572.2013.04.053
[14] 李永强, 周翔, 张霆.阿米福汀对肺癌放疗中不良反应的影响[J].现代肿瘤医学, 2010, 18(4):708-711. DOI:10.3969/j.issn.1672-4992.2010.04.27.
Li YQ, Zhou X, Zhang T. The effect of amifostine on toxicity of radiotherapy in lung cancer treatment[J]. Mod Oncol, 2010, 18(4):708-711.  doi: 10.3969/j.issn.1672-4992.2010.04.27
[15] 翁向群, 庄聪文, 程先进, 等.氨磷汀配合紫杉醇和顺铂同步放化疗治疗局部晚期非小细胞肺癌的临床分析[J].临床军医杂志, 2007, 35(6):817-819. DOI:10.3969/j.issn.1671-3826. 2007. 06. 004.
Weng XQ, Zhuang CW, Cheng XJ, et al. Clinical study on efficacy of compound amifostine with radiochemotherapy in treatment of local advanced NSCLC[J]. Clin J Med Office, 2007, 35(6):817-819.  doi: 10.3969/j.issn.1671-3826.2007.06.004
[16] Komaki R, Lee JS, Milas L, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer:report of a randomized comparative trial[J]. Int J Radiat Oncol Biol Phys, 2004, 58(5):1369-1377. DOI:10.1016/j.ijrobp.2003.10.005.
[17] Leong SS, Tan EH, Fong KW, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage Ⅲ non-small-cell lung cancer[J]. J Clin Oncol, 2003, 21(9):1767-1774. DOI:10.1200/JCO.2003.11.005.
[18] Antonadou D, Throuvalas N, Petridis A, et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2003, 57(2):402-408. DOI:10.1016/S0360-3016(03)00590-X.
[19] Antonadou D, Coliarakis N, Synodinou M, et al. Randomized phase Ⅲ trial of radiation treatment ±amifostine in patients with advanced-stage lung cancer[J]. Int J Radiat Oncol Biol Phys, 2001, 51(4):915-922. DOI:10.1016/S0360-3016(01)01713-8.
[20] Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy:a randomized phase Ⅱ study[J]. J Clin Oncol, 2000, 18(11):2226-2233. DOI:10.1200/JCO.2000.18.11.2226.
[21] Ricciuti B, Brambilla M, Metro G, et al. Targeting NTRK fusion in non-small cell lung cancer:rationale and clinical evidence[J]. Med Oncol, 2017, 34(6):105. DOI:10.1007/s12032-017-0967-5.
[22] Antonadou D. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer[J]. Semin Radiat Oncol, 2002, 12(1 suppl 1):S50-58. DOI:10.1053/srao.2002.31374.
[23] Koukourakis MI. Amifostine in clinical oncology:current use and future applications[J]. Anticancer Drugs, 2002, 13(3):181-209. DOI:10.1097/00001813-200203000-00001.